Cargando…

Decreased DNA Damage and Improved p53 Specificity of RITA Analogs

Reactivation of p53 tumor-suppressor function by small molecules is an attractive strategy to defeat cancer. A potent p53-reactivating molecule RITA, which triggers p53-dependent apoptosis in human tumor cells in vitro and in vivo, exhibits p53-independent cytotoxicity due to modifications by detoxi...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhan, Yue, Zhou, Xiaolei, Peuget, Sylvain, Singh, Madhurendra, Peyser, Brian D., Fan, Zhimin, Selivanova, Galina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9538593/
https://www.ncbi.nlm.nih.gov/pubmed/35877475
http://dx.doi.org/10.1158/1535-7163.MCT-22-0119
_version_ 1784803369874882560
author Zhan, Yue
Zhou, Xiaolei
Peuget, Sylvain
Singh, Madhurendra
Peyser, Brian D.
Fan, Zhimin
Selivanova, Galina
author_facet Zhan, Yue
Zhou, Xiaolei
Peuget, Sylvain
Singh, Madhurendra
Peyser, Brian D.
Fan, Zhimin
Selivanova, Galina
author_sort Zhan, Yue
collection PubMed
description Reactivation of p53 tumor-suppressor function by small molecules is an attractive strategy to defeat cancer. A potent p53-reactivating molecule RITA, which triggers p53-dependent apoptosis in human tumor cells in vitro and in vivo, exhibits p53-independent cytotoxicity due to modifications by detoxification enzyme Sulfotransferase 1A1 (SULT1A1), producing a reactive carbocation. Several synthetic modifications to RITA's heterocyclic scaffold lead to higher energy barriers for carbocation formation. In this study, we addressed the question whether RITA analogs NSC777196 and NSC782846 can induce p53-dependent apoptosis without SULT1A1-dependent DNA damage. We found that RITA analog NSC782846, but not NSC777196, induced p53-regulated genes, targeted oncogene addiction, and killed cancer cells upon p53 reactivation, but without induction of DNA damage and inhibition RNA pol II. Our results might demonstrate a method for designing more specific and potent RITA analogs to accelerate translation of p53-targeting compounds from laboratory bench to clinic.
format Online
Article
Text
id pubmed-9538593
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Association for Cancer Research
record_format MEDLINE/PubMed
spelling pubmed-95385932022-10-09 Decreased DNA Damage and Improved p53 Specificity of RITA Analogs Zhan, Yue Zhou, Xiaolei Peuget, Sylvain Singh, Madhurendra Peyser, Brian D. Fan, Zhimin Selivanova, Galina Mol Cancer Ther Small Molecule Therapeutics Reactivation of p53 tumor-suppressor function by small molecules is an attractive strategy to defeat cancer. A potent p53-reactivating molecule RITA, which triggers p53-dependent apoptosis in human tumor cells in vitro and in vivo, exhibits p53-independent cytotoxicity due to modifications by detoxification enzyme Sulfotransferase 1A1 (SULT1A1), producing a reactive carbocation. Several synthetic modifications to RITA's heterocyclic scaffold lead to higher energy barriers for carbocation formation. In this study, we addressed the question whether RITA analogs NSC777196 and NSC782846 can induce p53-dependent apoptosis without SULT1A1-dependent DNA damage. We found that RITA analog NSC782846, but not NSC777196, induced p53-regulated genes, targeted oncogene addiction, and killed cancer cells upon p53 reactivation, but without induction of DNA damage and inhibition RNA pol II. Our results might demonstrate a method for designing more specific and potent RITA analogs to accelerate translation of p53-targeting compounds from laboratory bench to clinic. American Association for Cancer Research 2022-10-07 2022-07-25 /pmc/articles/PMC9538593/ /pubmed/35877475 http://dx.doi.org/10.1158/1535-7163.MCT-22-0119 Text en ©2022 The Authors; Published by the American Association for Cancer Research https://creativecommons.org/licenses/by-nc-nd/4.0/This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.
spellingShingle Small Molecule Therapeutics
Zhan, Yue
Zhou, Xiaolei
Peuget, Sylvain
Singh, Madhurendra
Peyser, Brian D.
Fan, Zhimin
Selivanova, Galina
Decreased DNA Damage and Improved p53 Specificity of RITA Analogs
title Decreased DNA Damage and Improved p53 Specificity of RITA Analogs
title_full Decreased DNA Damage and Improved p53 Specificity of RITA Analogs
title_fullStr Decreased DNA Damage and Improved p53 Specificity of RITA Analogs
title_full_unstemmed Decreased DNA Damage and Improved p53 Specificity of RITA Analogs
title_short Decreased DNA Damage and Improved p53 Specificity of RITA Analogs
title_sort decreased dna damage and improved p53 specificity of rita analogs
topic Small Molecule Therapeutics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9538593/
https://www.ncbi.nlm.nih.gov/pubmed/35877475
http://dx.doi.org/10.1158/1535-7163.MCT-22-0119
work_keys_str_mv AT zhanyue decreaseddnadamageandimprovedp53specificityofritaanalogs
AT zhouxiaolei decreaseddnadamageandimprovedp53specificityofritaanalogs
AT peugetsylvain decreaseddnadamageandimprovedp53specificityofritaanalogs
AT singhmadhurendra decreaseddnadamageandimprovedp53specificityofritaanalogs
AT peyserbriand decreaseddnadamageandimprovedp53specificityofritaanalogs
AT fanzhimin decreaseddnadamageandimprovedp53specificityofritaanalogs
AT selivanovagalina decreaseddnadamageandimprovedp53specificityofritaanalogs